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Abstract
The application of family-based tests to whole-genome sequenced data provides a new window on the role of
rare variant alleles in the etiology of disease. By applying family-based tests to these data, we can now identify rare
variants associated with disease. Approaches for common variants, by contrast, require large sample sizes for
power, and are powerless when faced with rare variants. When we tested Yip et al’s 2011 family-based association
tests for rare variants on pedigrees from the Genetic Analysis Workshop 18, we found that weighted collapsing
methods generally have more power than unweighted methods, but are more prone to type I errors. We then
evaluated a sliding window modification of the weighted family-based association tests for rare variants method.
Although this modification inflates the rate of false positives, it significantly increases the power of family-based
association tests for rare variants to identify causal rare variants.
Background
Until next-generation sequencing (NGS) technology
became widely available, genetic studies, including gen-
ome-wide association studies (GWAS), were generally
based on the assumption that common diseases are dri-
ven by common variants (CD-CV). Although studies
based on the CD-CV approach have had some success
in identifying variants related to genetic disorders, their
performance with regard to more complex diseases
(such as hypertension or various psychiatric conditions)
has been limited at best [1]. Researchers today recognize
that most common disorders may result from the aggre-
gate effects of multiple rare variants [2].
Because disease-related variants are likely to be both
widespread in distribution and rare in frequency, GWAS
data, which covers only a small portion of the genome,
may not provide a representative sample in which to
find them. By contrast, whole genome sequencing
(WGS) technologies not only provide more complete
coverage of the genome, but also of individual variants
within genes. New ways to analyze and interpret WGS
data are needed, however, because WGS is still costly,
sample sizes are relatively small, and the disease-related
variants are rare. Toward that end, family-based associa-
tion test (FBAT) analyses, which enrich the occurrence of
rare variants within pedigrees, provide a new approach to
identify rare and possibly disease-related variants. This
study shows how well the pedigree-based FBAT-rare
method developed by Yip et al [3] performs when applied
to WGS data from extended families for the identifica-
tion of rare causal variants underlying complex traits
such as blood pressure.
Methods
Data description
In this study, 2 FBAT-rare methods of statistical analysis
were tested on the Genetic Analysis Workshop 18
(GAW18) data set based on the San Antonio Family
Studies. GAW18 data includes 1389 individuals in 20
large pedigrees, with a maximum of 5 generations per
pedigree. Subjects are randomly selected low-income
Mexican Americans and their extended pedigree mem-
bers. Study probands range in age, on average, between
40 and 60 years. The genotype data is cleared of mende-
lian errors on odd-numbered chromosomes, and comes
from 959 individuals. Of these, 464 were sequenced at
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60× coverage. Data from the rest were imputed. In total,
the genotype data used in this study included 8,348,674
variants. For the purpose of assessing statistical methods, a
set of genes were selected and their effect sizes calculated
based on their correlation with hypertension, as well as
their PolyPhen scores; 200 replicates of phenotypes were
simulated. This set of genes is listed in the GAW18
answers. For convenience, we refer to the genes used to
simulate phenotypes as true causal genes and the rest as
noncausal. With this information, we assessed the power
and false-positive rates of FBAT-rare, [3]. The method
itself is not affected by our knowledge of the answer.
Analytical Methods
Family-based association tests for rare variants (FBAT-rare)
In collapsing methods of statistical analysis, the effects of
individual rare variants are combined linearly and the
resulting sum is treated as a single variant. Many studies
have been conducted to develop collapsing algorithms
powerful enough to detect rare variants [4]. FBAT-rare
tests, however, are among the first to apply collapsing
methods to the analysis of pedigree-based data [3].
In this study, we investigated 2 different weighting
schemes for test statistics implemented in the FBAT
software (FBAT v2.0.4 beta 1). Under the FBAT-v0 test,
the weights are defined as: 1, that is wk = 1, k = 1, ...,M,
whereas under the FBAT-v1 test, the weights are
defined as: wk = 1/
√
ζpk(1− pk), k = 1, ...,M, where ζ is
the total number of nuclear families and pk is the allele
frequency for the kth variant estimated from the sample.
This weight scheme follows that used by Madsen and
Browning [5] to estimate allele frequencies in controls
sampled from the general population. (Note that both
FBAT-v0 and FBAT-v1 are 2-sided tests that have now
been implemented in FBAT v2.0.4 beta 1.)
Both methods were tested for each gene on chromo-
some 3 and repeated 200 times for each replicate, result-
ing in 200 p values for each gene. We observed that these
p values often differ from each other by several orders of
magnitude, preventing us from averaging all 200. Thus,
we needed appropriate measures to compare different
genes. To achieve this, we looked at a decreasing series of
powers of 10. For an arbitrary gene, we calculated the
fraction of p values that falls below 1*10−i+1 (Table 1) and
defined this as the power of finding the gene at the
threshold of 10−i. Then, we find the smallest 10−x, such
that this fraction is strictly above 0.5, and call it the
power of both tests, to simplify comparisons.
Results
FBAT-rare methods
This study focused solely on chromosome 3. We defined
genes according to the hg19 database (http://hgdownload.
cse.ucsc.edu/goldenpath/hg19/database/). To highlight the
statistical properties of rare variants, we selected variants
with minor allele frequencies (MAFs) of <0.01, based on
the founder population, for each gene. Using both v0 and
v1 methods, we collapsed rare variants for each gene into a
single variant. Both methods were then applied to all 200
replicates of simulated phenotype data, with the focus on
the SBP_1 trait, which is the first systolic blood pressure
measurement out of 4. Possible effects of sex, age, and
medication on SBP_1 were taken into account to generate
a corrected ASBP_1 phenotype, which was then analyzed
in the same way as the uncorrected SBP_1 phenotype.
Our assessment of the FBAT-rare methods’ power to
detect causal variants and their susceptibility to type I
error is based on the p values derived, as described below,
for all genes. In the first task, the power of FBAT-rare
methods (calculated as the proportion of collapsed var-
iants with p values within the range of significance) was
tested using true causal genes from chromosome 3 (see
Table 1). The rate of type I errors was calculated using
noncausal genes (Figure 1).
Of the true causal genes, collapsed rare variants within
MAP4 gave the strongest signal for significant association
with the phenotype of interest. Both FBAT-v0 and
FBAT-v1 methods detected these association signals,
with p values of less than 10−4, in MAP4. In the SCAP
gene, by contrast, only the v1 method detected associa-
tions at this level of significance, and neither method
detected associations in other causal genes (data not
shown, except for ARHGEF3). Based on our results for
all causal genes, it is clear that the v1 method consistently
outperforms the v0 method and is more sensitive than v0
Table 1 Power of FBAT-rare methods by p value of true-
positive variants detected
Significance level p Value threshold
10−7 10−6 10−5 10−4
Genes analyzed Power
MAP4
v0 0 0 0.125 1
v1 0.005 0.955 1 1
v0 corrected 0 0 0.12 1
v1 corrected 0.03 0.94 1 1
SCAP
v0 0 0 0 0
v1 0 0.005 0.975 1
v0 corrected 0 0 0 0.015
v1 corrected 0 0.085 1 1
ARHGEF3
v0 0 0 0 0
v0 corrected 0 0 0 0
v1 0 0 0 0
v1 corrected 0 0 0 0
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for the detection of causal variants. In our data, if the p
value for v1 falls below 0.1, then the v1 test consistently
performs better than v0 for all cases tested.
To assess the validity of both methods, we selected all
noncausal genes from chromosome 3 (using the same
procedures that were used to calculate the power of cau-
sal genes) to calculate the probability of chance findings.
See Figure 1 for the results, using v0 and v1 methods,
with both the corrected and uncorrected phenotypes.
At the significance threshold p value of 10−3, both
FBAT-rare methods identify fewer than 6% of significant
associations in the 1209 noncausal genes. When the num-
ber of false positives decreases as the threshold becomes
more stringent, even at the10−6 threshold, the FBAT-rare
methods identify significant associations in 2% of the non-
causal genes. In addition, the v1 method, which is defi-
nitely more sensitive than the v0 method, is also
unambiguously more prone to identifying false positives.
Whether the phenotype is adjusted or unadjusted, though,
does not appear to affect type I error rates.
Sliding-window approach
That of 31 true causal genes simulated on chromosome
3, only MAP4 and SCAP were detected at the 10−4 sig-
nificance level, indicates that neither the FBAT-v1 nor
the FBAT-v0 method has ample power to detect rare
variants. Because small genes are easier to detect than
large genes, however, we decided to compensate for
gene size using a sliding-window approach.
First, we divided the entire chromosome into a series of
disjointed 100-kilobase (kb) windows with the whole
100kb points on the genetic positions (0-100 kb, 100-200
kb,...) as the starting and ending points. Using MAP4 as
an example, the entire genetic region spans across 4 such
windows. The reasoning is that any clustering of causal
variants to fall within such a window will show up promi-
nently. We then tested for rare variants using FBAT-v1
on data from each window, in the same manner as we
tested the 2 FBAT methods on individual genes. MAP4
results (Figure 2) show that while the 47800 to 47900 kb
and 48100 to 48200 kb windows contain data from a por-
tion of the MAP4 region, they do not contain any of the
causal variants. The 48100 to 48200 kb window still exhi-
bits a significant signal in the p = 10−6 region, for a result
that is as good as that achieved when FBAT-v1 is
applied to MAP4 as a whole. Although the 47800 to
47900 kb window contains no signals of that strength, it
reached a respectable power of 10−4, which can be par-
tially explained by the high level of intermarker
linkage disequilibrium between the 2 regions and MAP4
(data not shown).
For windows completely contained within MAP4,
FBAT-v1 detected variants in the 47900 to 48000 kb and
48100 to 48200 kb windows with the same power as the
gene-based method, and in the 48000 to 48100 kb win-
dow, detection even reached a power of 10−7, a whole
magnitude better than a gene-based analysis of MAP4 can
achieve. With most causal genes, results from FBAT-rare
v1 analysis of the best window are an order of magnitude
better than the results from gene-based analysis. The slid-
ing-window approach, however, tends to result in more
false positives (data not shown).
Because we used windows with a fixed length of 100 kb,
the number of tests we did varies by the length of the
gene. The MAP4 gene for example, spans 4 windows.
Larger genes spanning more windows would be subjected
to more tests, whereas smaller genes spanning only 1
window are tested only once. In genes that span more
Figure 1 Type I errors generated by FBAT-v0 and FBAT-v1 analysis of adjusted and unadjusted phenotypes at 4 different p value
thresholds.
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than 1 window, multiple testing becomes an issue. In the
case of MAP4, because the gene’s 9 rare causal variants all
fall within the 2 windows (see Figure 2), using Bonferroni
correction would effectively double its p-values. When we
applied the Bonferroni correction, the power of the best
performing window at 10−7 fell from 0.745 to 0.455. Both,
however, far outclass the power of the MAP4 gene evalu-
ated as a whole, which stands at 0.005 at the threshold of
10−7. Even if more stringent corrections were applied, the
sliding-window approach would still have better power
than the gene-based approach. Therefore, in the case of
MAP4, correcting for multiple testing does not erase the
power gain resulting from the sliding window approach.
Discussion
In this study, we analyzed the GAW18 data set using 2
FBAT-rare methods (v0 and v1) to assess their power
to detect rare causal variants associated with complex
diseases. Results from these tests show that the weighed
v1 method has better detecting power than the v0 method
(see Table 1) but is more prone to type I errors (see
Figure 1). With both methods, the only 2 positive hits for
true causal genes to reach a level of significance were in
the MAP4 (p = 10−6) and SCAP (p =10−5) genes. Both
methods failed to detect the other simulated true causal
genes at more than a 10−4 level of significance. Both suffer
from elevated type I error with roughly 6% of hits reaching
levels of high significance (p value of 10−3).
We noticed that larger genes were more likely to be
penalized when using the collapsing method. To see if
we could improve these results, we reanalyzed the data
with the FBAT-v1 method using a sliding-window
approach. Our reasoning is that since the result for the
collapsing method depends largely on the relative pro-
portion of causal rare variants within a gene, breaking
large genes into several windows would remove the
diluting effect that regions with no causal variants have
on the power of association tests.
Our results indicated that the sliding window
approach did improve the v1 method’s performance in
detecting causal rare variants for large genes. However,
when genes are broken down into multiple windows,
the question arises whether the power gain is an illusion
caused by multiple testing. To address this concern, we
applied Bonferroni correction on the best-performing
window of MAP4, and found that although the power
decreased compared to the uncorrected results, it is still
significantly higher than what MAP4 as a whole
achieved. This confirmed that at least in the case of
MAP4, the power improvement resulting from the slid-
ing window approach was real. However, multiple test-
ing corrections would be harsher for large genes that
span many windows. Therefore, we do not dispute that
in some cases the power gain when using the sliding
window approach is a result of multiple testing alone.
We note that the relatively modest performance of the
2 FBAT-rare methods may reflect the limited size of our
sample and the rarity of minor alleles. The fact that
many of the simulated variants had only a modest effect
does not help to distinguish them from background
noise, and information is lost when the FBAT software
breaks large pedigrees into nuclear families. Finally,
Figure 2 Performance of sliding window analysis of MAP4 gene. Blue and green drop lines show the positions of causal variants on MAP4
and the effect size for the adjusted systolic blood pressure trait. The green line represents the actual MAP4 region. The red line indicates the
position of the 4 sequential windows, and its height shows the power of each window to detect rare variants. The purple line represents the
power attained by analysis of MAP4 as a whole.
Xu et al. BMC Proceedings 2014, 8(Suppl 1):S31
http://www.biomedcentral.com/1753-6561/8/S1/S31
Page 4 of 5
linkage disequilibrium could have led to inflated num-
bers of false positives.
Our future studies will focus on comparing the FBAT-
v0/v1 with alternative methods such as Betafam, proposed
by Guo and Shugart [6], as well as developing novel meth-
ods that preserve the structure and thus the information
contained in complex pedigrees.
Conclusions
We tested 2 family-based association tests for rare variants
(FBAT-rare) on 20 pedigrees provided by the GAW18,
and our results indicated that weighted collapsing meth-
ods have more power than unweighted methods and
inflated type I errors. We also applied a sliding-window
approach to the same data sets. Although that approach
tends to inflate the false-positive rates, it does significantly
increase the power to identify some of the causal rare var-
iants in GAW18 data.
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